Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus Vaccines
Studies from University of Melbourne in the area of hepatitis C virus vaccines published
October 8th, 2008
Current study results from the report, 'A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection,' have been published. "Effective CD8(+) T cell responses have been induced using totally synthetic self-adjuvanting lipopeptides containing the dipalmitoyl-S-glyceryl cysteine lipid moiety, which is a ligand for Toll-like receptor 2 (TLR2) on dendritic cells (DC). In this study, we evaluated the use of lipopeptide vaccine candidates containing HLA-A2-restricted epitopes for DC-based immunotherapy of HCV infection," investigators in Parkville, Australia report. "Lipopeptides were able to induce specific CD8(+) T cell responses...
Source: Vaccine Weekly (2008-10-08)
|
